drug

CGT4255

1 story · latest Nov 5, 2026

Follow CGT4255. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Cogent Biosciences, Inc.

Timeline

Cogent reports Q3 2026 results, three bezuclastinib PDUFA dates ahead

Nov 5Quarterly updatebezuclastinib Cogent Biosciences, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.